Fulcrum Therapeutics, Inc.

NasdaqGM:FULC Stock Report

Market Cap: US$162.1m

Fulcrum Therapeutics Valuation

Is FULC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FULC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate FULC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate FULC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FULC?

Key metric: As FULC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for FULC. This is calculated by dividing FULC's market cap by their current revenue.
What is FULC's PS Ratio?
PS Ratio2x
SalesUS$80.87m
Market CapUS$162.09m

Price to Sales Ratio vs Peers

How does FULC's PS Ratio compare to its peers?

The above table shows the PS ratio for FULC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.5x
ACRS Aclaris Therapeutics
8.3x13.0%US$146.4m
ESPR Esperion Therapeutics
1.4x31.1%US$417.7m
SNDL SNDL
0.8x7.2%US$517.7m
ETON Eton Pharmaceuticals
7.5x31.0%US$258.9m
FULC Fulcrum Therapeutics
2x-91.5%US$162.1m

Price-To-Sales vs Peers: FULC is good value based on its Price-To-Sales Ratio (2x) compared to the peer average (4.5x).

Price to Sales Ratio vs Industry

How does FULC's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

68 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$3.87b
PRGO Perrigo
0.8x3.4%US$3.66b
BHC Bausch Health Companies
0.3x1.5%US$3.12b
SNDL SNDL
0.8x7.2%US$517.73m
FULC 2.0xIndustry Avg. 2.4xNo. of Companies68PS03.67.210.814.418+
68 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: FULC is good value based on its Price-To-Sales Ratio (2x) compared to the US Pharmaceuticals industry average (2.4x).

Price to Sales Ratio vs Fair Ratio

What is FULC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FULC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2x
Fair PS Ratio0.04x

Price-To-Sales vs Fair Ratio: FULC is expensive based on its Price-To-Sales Ratio (2x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FULC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.03
US$5.29
+74.4%
70.6%US$14.00US$2.00n/a7
Nov ’25US$3.21
US$5.29
+64.7%
70.6%US$14.00US$2.00n/a7
Oct ’25US$3.60
US$5.29
+46.8%
70.6%US$14.00US$2.00n/a7
Sep ’25US$8.55
US$16.11
+88.4%
33.8%US$26.00US$5.00n/a9
Aug ’25US$9.01
US$16.11
+78.8%
33.8%US$26.00US$5.00n/a9
Jul ’25US$6.31
US$15.78
+150.0%
31.0%US$23.00US$5.00n/a9
Jun ’25US$7.85
US$15.78
+101.0%
31.0%US$23.00US$5.00n/a9
May ’25US$7.33
US$13.25
+80.8%
35.7%US$19.00US$5.00n/a8
Apr ’25US$9.31
US$13.25
+42.3%
35.7%US$19.00US$5.00n/a8
Mar ’25US$10.99
US$13.07
+18.9%
39.6%US$19.00US$4.50n/a7
Feb ’25US$8.02
US$10.36
+29.1%
38.5%US$16.00US$4.50n/a7
Jan ’25US$6.75
US$10.21
+51.3%
40.7%US$16.00US$4.50n/a7
Dec ’24US$4.99
US$10.21
+104.7%
40.7%US$16.00US$4.50n/a7
Nov ’24US$3.75
US$10.21
+172.4%
40.7%US$16.00US$4.50US$3.217
Oct ’24US$4.44
US$10.21
+130.1%
40.7%US$16.00US$4.50US$3.607
Sep ’24US$5.72
US$10.57
+84.8%
35.8%US$16.00US$4.50US$8.557
Aug ’24US$3.71
US$8.07
+117.6%
53.8%US$16.00US$4.00US$9.017
Jul ’24US$3.30
US$8.07
+144.6%
53.8%US$16.00US$4.00US$6.317
Jun ’24US$2.89
US$7.44
+157.4%
59.1%US$16.00US$3.00US$7.858
May ’24US$2.72
US$9.63
+253.9%
47.9%US$20.00US$5.00US$7.338
Apr ’24US$2.85
US$9.33
+227.5%
47.4%US$20.00US$5.00US$9.319
Mar ’24US$6.29
US$17.22
+173.8%
48.2%US$35.00US$5.00US$10.999
Feb ’24US$12.62
US$22.56
+78.7%
33.3%US$35.00US$8.00US$8.029
Jan ’24US$7.28
US$21.89
+200.7%
39.1%US$35.00US$8.00US$6.759
Dec ’23US$6.70
US$21.89
+226.7%
39.1%US$35.00US$8.00US$4.999
Nov ’23US$5.80
US$29.57
+409.9%
24.4%US$42.00US$20.00US$3.757

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.6b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.49

7D

-5.1%

1Y

74.5%

Collegium Pharmaceutical

US$954.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.22

7D

-9.2%

1Y

14.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.25

7D

-10.5%

1Y

7.7%